Dublin, May 16, 2019 (GLOBE NEWSWIRE) -- The "China Independent Clinical Laboratory Industry Report, 2019-2025" report has been added to ResearchAndMarkets.com's offering.

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below the 40% or more seen in Europe, the United States, and Japan. The main reason for this is that the laboratory and pathology departments of public hospitals occupy the leading position in the industry in China.

In China, large independent clinical laboratories can provide more than 2,000 test items, while first-class AAA hospitals can only offer over 300-500 test items. With the acceleration of population aging, the higher incidence of various chronic diseases and favorable policies, the penetration rate and scale of China's independent clinical laboratory industry will increase year by year.

China's independent clinical laboratory market size enjoyed a CAGR of 40.9% during 2010-2018 and stood at RMB18.6 billion in 2018, a year-on-year increase of 37.8%. By 2025, it is expected to reach RMB96.7 billion with the growth rate of above 20%.

As of September 2018, there had been 1,271 independent clinical laboratories in China, indicating gradually intensified competition in the industry. At present, major players in China include KingMed Diagnostics, ADICON, DIAN Diagnostics, DAAN Gene, MedicalSystem Biotechnology and others. KingMed Diagnostics is the industry's leader with a 22.8% market share in 2018.

As the competition intensifies, the market share of KingMed Diagnostics has reduced from 32.9% in 2014 to 22.8% in 2018. In the future, small ICL companies without competitive advantages are likely to be phased out and the industry will become more concentrated.

The report highlights the following:

• Overview of China's independent clinical laboratory industry, covering development environment, status quo, market size, competitive landscape, and development trend
• Upstream and downstream sectors of China's independent clinical laboratory industry
• Operation, gross margin, R&D investment, independent clinical laboratory business and development strategy of 21 companies in China

Key Topics Covered

1. Overview of Independent Clinical Laboratory
1.1 Definition
1.2 Industry Chain

2. Overview of China Independent Clinical Laboratory Industry
2.1 Policy Environment
2.1.1 Access Policy
2.1.2 Industry Policy
2.2 International Environment
2.2.1 Status Quo
2.2.2 Benchmarking Enterprises
2.3 Status Quo
2.4 Market size
2.5 Competitive Landscape
2.6 Development Trends
2.6.1 Industry Scale Expands Constantly
2.6.2 Hierarchical Medical System Will Boost the Rapid Development of the Industry
2.6.3 The Laboratory Outsourcing Proportion of Public Hospitals Will Rise due to Cost Control
2.6.4 High-end Test Items Will Make More Revenue Contribution
2.6.5 The Rapid Development of Private Hospitals Will Stimulate the Demand in the Independent Clinical Laboratory Market
2.6.6 Independent Clinical Laboratory Institutions Will Become Technical Leaders amid Quick Technological Upgrades
2.6.7 The Aging Population Balloons and the Demand for Medical Laboratory Will Soar
2.6.8 Internet Will Stimulate the Business Model Upgrade of Independent Clinical Laboratory Industry
2.6.9 Intensified industry competition Forced Small Capacity to Withdraw

3. Upstream and Downstream Sectors of China Independent Clinical Laboratory Industry
3.1 Upstream Sector
3.1.1 Status Quo
3.1.2 Market Size
3.1.3 Competitive Landscape
3.1.4 Development Trend
3.2 Downstream Sector
3.2.1 Quantity
3.2.2 Medical Services
3.2.3 Revenue
3.2.4 Health Costs

4. Key Players
4.1 KingMed Diagnostics
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D and Investment
4.1.6 Major Customers
4.1.7 Independent Clinical Laboratory Business
4.1.8 Development Strategy
4.2 DIAN Diagnostics
4.3 Shanghai Labway Clinical Laboratory
4.4 DAAN Gene
4.5 ADICON Clinical Laboratories
4.6 NYMPHAVN Biotechnology
4.7 SurExam Biotechnology
4.8 MedicalSystem Biotechnology
4.9 Beijing Lawke Health Laboratory
4.10 Beijing Lepu Gene Technology
4.11 Shanghai Biotecan Pharmaceuticals
4.12 Jiangsu Superbio Life Science
4.13 Amoy Diagnostics
4.14 Guangdong Hybribio Biotech
4.15 Other Enterprises
4.15.1 Kindstar Global
4.15.2 CapitalBio Corporation
4.15.3 Beijing Adinovo Gene Technology Co. Ltd.
4.15.4 Deyi Diagnostics
4.15.5 IPE Center for Clinical Laboratory
4.15.6 Centre Testing International Group Co. Ltd. (CTI)
4.15.7 SinoPath Diagnosis

For more information about this report visit https://www.researchandmarkets.com/r/greafz

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Laboratory Testing